Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right

Carl E. Ruby, Melissa A. Yates, Daniel Hirschhorn-Cymerman, Peter Chlebeck, Jedd D. Wolchok, Alan N. Houghton, Halina Offner, Andrew D. Weinberg

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

We report that OX40 stimulation drives all lineages of CD4 T cell development, including regulatory T cells (Tregs), and the plasticity of the response is dependant on local cytokines. In TGF-β1-treated cultures, an OX40 agonist increased IFN-γ and IL-4 production and diverted T cells from the Treg lineage. However, cytokine blockade in the context of OX40 stimulation promoted enhanced Treg accumulation. This observation was evident in naive mice, as OX40 engagement enhanced Treg proliferation and accumulation in vivo. Lastly, OX40 agonist administration influenced experimental autoimmune encephalomyelitis disease severity in opposing directions, depending on the timing of administration. Given during Ag priming, the OX40 agonist drove Treg expansion and inhibited disease, whereas given later it enhanced T cell effector cytokine production in the CNS and exacerbated disease. Hence, OX40 signaling can augment the accumulation of all CD4 T cell lineages; however, its accentuation of immune responses may have vastly different biologic outcomes depending upon the local cytokine milieu.

Original languageEnglish (US)
Pages (from-to)4853-4857
Number of pages5
JournalJournal of Immunology
Volume183
Issue number8
DOIs
StatePublished - Oct 15 2009

Fingerprint

Regulatory T-Lymphocytes
Cytokines
T-Lymphocytes
Cell Lineage
Central Nervous System Diseases
Interleukin-4
Autoimmune Diseases

ASJC Scopus subject areas

  • Immunology

Cite this

Ruby, C. E., Yates, M. A., Hirschhorn-Cymerman, D., Chlebeck, P., Wolchok, J. D., Houghton, A. N., ... Weinberg, A. D. (2009). Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. Journal of Immunology, 183(8), 4853-4857. https://doi.org/10.4049/jimmunol.0901112

Cutting edge : OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. / Ruby, Carl E.; Yates, Melissa A.; Hirschhorn-Cymerman, Daniel; Chlebeck, Peter; Wolchok, Jedd D.; Houghton, Alan N.; Offner, Halina; Weinberg, Andrew D.

In: Journal of Immunology, Vol. 183, No. 8, 15.10.2009, p. 4853-4857.

Research output: Contribution to journalArticle

Ruby, CE, Yates, MA, Hirschhorn-Cymerman, D, Chlebeck, P, Wolchok, JD, Houghton, AN, Offner, H & Weinberg, AD 2009, 'Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right', Journal of Immunology, vol. 183, no. 8, pp. 4853-4857. https://doi.org/10.4049/jimmunol.0901112
Ruby CE, Yates MA, Hirschhorn-Cymerman D, Chlebeck P, Wolchok JD, Houghton AN et al. Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. Journal of Immunology. 2009 Oct 15;183(8):4853-4857. https://doi.org/10.4049/jimmunol.0901112
Ruby, Carl E. ; Yates, Melissa A. ; Hirschhorn-Cymerman, Daniel ; Chlebeck, Peter ; Wolchok, Jedd D. ; Houghton, Alan N. ; Offner, Halina ; Weinberg, Andrew D. / Cutting edge : OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. In: Journal of Immunology. 2009 ; Vol. 183, No. 8. pp. 4853-4857.
@article{33f0d1a8a95b4de287741703a871f2dd,
title = "Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right",
abstract = "We report that OX40 stimulation drives all lineages of CD4 T cell development, including regulatory T cells (Tregs), and the plasticity of the response is dependant on local cytokines. In TGF-β1-treated cultures, an OX40 agonist increased IFN-γ and IL-4 production and diverted T cells from the Treg lineage. However, cytokine blockade in the context of OX40 stimulation promoted enhanced Treg accumulation. This observation was evident in naive mice, as OX40 engagement enhanced Treg proliferation and accumulation in vivo. Lastly, OX40 agonist administration influenced experimental autoimmune encephalomyelitis disease severity in opposing directions, depending on the timing of administration. Given during Ag priming, the OX40 agonist drove Treg expansion and inhibited disease, whereas given later it enhanced T cell effector cytokine production in the CNS and exacerbated disease. Hence, OX40 signaling can augment the accumulation of all CD4 T cell lineages; however, its accentuation of immune responses may have vastly different biologic outcomes depending upon the local cytokine milieu.",
author = "Ruby, {Carl E.} and Yates, {Melissa A.} and Daniel Hirschhorn-Cymerman and Peter Chlebeck and Wolchok, {Jedd D.} and Houghton, {Alan N.} and Halina Offner and Weinberg, {Andrew D.}",
year = "2009",
month = "10",
day = "15",
doi = "10.4049/jimmunol.0901112",
language = "English (US)",
volume = "183",
pages = "4853--4857",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "8",

}

TY - JOUR

T1 - Cutting edge

T2 - OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right

AU - Ruby, Carl E.

AU - Yates, Melissa A.

AU - Hirschhorn-Cymerman, Daniel

AU - Chlebeck, Peter

AU - Wolchok, Jedd D.

AU - Houghton, Alan N.

AU - Offner, Halina

AU - Weinberg, Andrew D.

PY - 2009/10/15

Y1 - 2009/10/15

N2 - We report that OX40 stimulation drives all lineages of CD4 T cell development, including regulatory T cells (Tregs), and the plasticity of the response is dependant on local cytokines. In TGF-β1-treated cultures, an OX40 agonist increased IFN-γ and IL-4 production and diverted T cells from the Treg lineage. However, cytokine blockade in the context of OX40 stimulation promoted enhanced Treg accumulation. This observation was evident in naive mice, as OX40 engagement enhanced Treg proliferation and accumulation in vivo. Lastly, OX40 agonist administration influenced experimental autoimmune encephalomyelitis disease severity in opposing directions, depending on the timing of administration. Given during Ag priming, the OX40 agonist drove Treg expansion and inhibited disease, whereas given later it enhanced T cell effector cytokine production in the CNS and exacerbated disease. Hence, OX40 signaling can augment the accumulation of all CD4 T cell lineages; however, its accentuation of immune responses may have vastly different biologic outcomes depending upon the local cytokine milieu.

AB - We report that OX40 stimulation drives all lineages of CD4 T cell development, including regulatory T cells (Tregs), and the plasticity of the response is dependant on local cytokines. In TGF-β1-treated cultures, an OX40 agonist increased IFN-γ and IL-4 production and diverted T cells from the Treg lineage. However, cytokine blockade in the context of OX40 stimulation promoted enhanced Treg accumulation. This observation was evident in naive mice, as OX40 engagement enhanced Treg proliferation and accumulation in vivo. Lastly, OX40 agonist administration influenced experimental autoimmune encephalomyelitis disease severity in opposing directions, depending on the timing of administration. Given during Ag priming, the OX40 agonist drove Treg expansion and inhibited disease, whereas given later it enhanced T cell effector cytokine production in the CNS and exacerbated disease. Hence, OX40 signaling can augment the accumulation of all CD4 T cell lineages; however, its accentuation of immune responses may have vastly different biologic outcomes depending upon the local cytokine milieu.

UR - http://www.scopus.com/inward/record.url?scp=77949654340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949654340&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0901112

DO - 10.4049/jimmunol.0901112

M3 - Article

C2 - 19786544

AN - SCOPUS:77949654340

VL - 183

SP - 4853

EP - 4857

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 8

ER -